{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gormley M"],"funding":["Cancer Research UK","NIDCR NIH HHS","World Health Organization","University of Bristol","NIEHS NIH HHS","GENCAPO/FAPESP","National Institutes of Health","Academy of Medical Sciences","World Cancer Research Fund","Medical Research Council","Diabetes UK","National Institute for Health Research (NIHR)","National Institute of Dental and Craniofacial Research","NCI NIH HHS","Division of Cancer Prevention, National Cancer Institute","Wellcome Trust"],"pagination":["e1009525"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8096036"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(4)"],"pubmed_abstract":["Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk using two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in HMGCR, NPC1L1, CETP, PCSK9 and LDLR were used to proxy th"],"journal":["PLoS genetics"],"pubmed_title":["Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study."],"pmcid":["PMC8096036"],"funding_grant_id":["C18281/A19169","10/51168-0","de Pass VC Research Fellowship","C68933/A28534","28534","17/0005587","SBF004\\1079","R01 CA090731","P50 CA097190","P30 CA016086","1X01HG007780-0","C18281/A29019","IIG_2019_2009","MC_QA137853","R01-CA90731","MC_UU_00011/7","MC_PC_17228","NIHR202411","MC_UU_00011/1","P30 ES010126","29019","220530/Z/20/Z","ACF-2019-25-015","001","P30 CA047904","R01 DE025712","RP-PG-0707-10034"],"pubmed_authors":["Dudding T","Diergaarde B","Brennan P","Richmond RC","Tajara EH","Yarmolinsky J","Boccia S","Olshan AF","Gormley M","Ness AR","Burrows K","Thomas S","Davey Smith G","Hung RJ","Tyrrell J","Vincent EE","Martin RM","Severino P","Lacko M","Pring M","Legge D","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.","description":"Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk using two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in HMGCR, NPC1L1, CETP, PCSK9 and LDLR were used to proxy th","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-08T07:01:05.914Z","creation":"2024-11-21T00:54:25.337Z"},"accession":"S-EPMC8096036","cross_references":{"pubmed":["33886544"],"doi":["10.1371/journal.pgen.1009525"]}}